News

Pending results from the ENGOT-en9/LEAP-001 will determine whether the combination of pembrolizumab and lenvatinib prolongs survival more than chemotherapy in patients with endometrial cancer.

Results presented during the 2022 Gastrointestinal Cancers Symposium showed that 58.6% of evaluable patients experienced complete regression and fibrosis with no tumor cells.

American Oncology network has announced that the organization is partnering with Rapides Cancer Center to provide advanced, comprehensive, and convenient care for patients in Central Louisiana.

A medical oncologist, Shalin R. Shah, DO, is the newest member of the American Oncology Network's executive board.

An overall survival improvement for the combination of durvalumab and tremelimumab has been reported by the HIMALAYA clinical trial lead investigator.

TOPAZ-1 results reveal promise for durvalumab administered in combination with gemcitabine and cisplatin to patients with advanced biliary tract cancer.

Gedatolisib has earned attention from the FDA after demonstrating encouraging efficacy and safety in a phase 1b clinical trial.

During a recent medical meeting, Michael Lowe, MD, MA, FACS, FSSO, and Ragini Kudchadkar, MD, debated adjuvant therapy versus neoadjuvant for the treatment of resectable stage III melanoma.

In an interview with Targeted Oncology, Jennifer Brown, MD, PhD discussed the early analysis of the SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia and deletion 17p.

Margarett C. Ellison, MD, MHA, FACS, FACOG, gynecologic oncologist for Gynecologic Oncology of Tallahassee, a Division of Florida Cancer Specialists & Research Institute, reviews potential immunotherapy treatments for Cervical Cancer Awareness Month.

The FDA is reviewing a supplemental biologics license application for cemiplimab-rwlc in combination with chemotherapy as a first-line treatment option for patients with advanced non-small cell lung cancer.

Retrospective data show that only 24% of patients treated with immune checkpoint inhibitors required immunosuppression while the rest recovered over time.

A study of cinrebafusp alfa is underway to evaluate its safety and efficacy in combination with other therapies in patients with gastric or gastroesophageal junction cancers.

Without confirmed clinical benefit in follicular lymphoma and small lymphocytic leukemia, idelalisib's indications for these malignancies were withdrawn from the United States market.

A fast track designation has been granted to CYNK-101 in combination with standard frontline chemotherapy, trastuzumab, and pembrolizumab for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

At the 63rd ASH Annual Meeting and Exposition, studies highlighted the promise of Bruton's tyrosine kinase inhibitors for the treatment of patients with mantle cell lymphoma and what oncologists should do after Bruton's tyrosine kinase inhibition.

The FDA has accepted a supplement biologics license application for fam-trastuzumab deruxtecan-nxki and granted it priority review for the treatment of adult patients with unresectable or HER2-positive metastatic breast cancer who have received a prior anti-HER2- based regimen.

The phase 2/3 GRANITE-CRC-1L clinical trial has been initiated.

The immunotherapy combination of nivolumab and ipilimumab did not extend progression-free survival in patients with small cell lung cancer when compared with placebo.

Phase 3 study findings show that paclitaxel combined carboplatin stands up to the combination of paclitaxel and ifosfamide for the treatment of patients with uterine carcinosarcoma.

With rusfertide, clinical trial investigators are poised to fill a clinical gap by addressing iron deficiency in patients with polycythemia vera.

A phase 2b study aims to confirm positive efficacy and safety results previously reported with the combination of maveropepimut-S and pembrolizumab in patients with relapsed or refractory diffuse large B-cell lymphoma.

In patients with recurrent and/or metastatic cervical cancer, the second-line combination of balstilimab and zalifrelimab may offer meaningful clinical benefit, but further research is needed.

Mark Roschewski, MD, discusses how different large cell lymphoma subtypes may respond to different therapies.

Although nivolumab did not significantly outperform sorafenib in the CheckMate 459 of patients with advanced hepatocellular carcinoma, positive resuls were shown for the secondary end points.

Results from the phase 2 OCEAN trial show that osimertinib is effective in treating central nervous system metastases from non–small cell lung cancer in patients with certain mutations.

The FDA granted both a regenerative medicine advanced therapy and fast track designation to C-CAR039 for relapsed or refractory diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Ronald S. Go, MD, discussed the new guidelines for the diagnosis and treatment of histiocytic neoplasms, challenges with managing the disease, and toxicity management.

Richard T. Silver, MD, discusses which patients with myeloproliferative neoplasms may derive the most benefit from recombinant interferon alpha, based on prior research in the chronic myeloid leukemia space and in patients with myeloproliferative neoplasms.

The target number of patients with advanced renal cell carcinoma has been enrolled in the phase 3 CONTACT-3 trial, which aims to determine the efficacy and safety of cabozantinib combined with atezolizumab.